Fluoxakalner
Fluoxakalner is a K v 7.2 and K v 7.3 potassium channel opener which is under investigation for potential medical use.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Fluoxakalner is a K v 7.2 and K v 7.3 potassium channel opener which is under investigation for potential medical use. Its for opening K v 7.2 and K v 7.3 channels has been found to be 360 nM. The drug produces analgesic effects in rodents and without causing sedation or locomotor changes.
In addition, it did not inhibit various cardiac ion channels. The chemical synthesis of fluoxakalner has been described. Fluoxakalner was first described in the scientific literature by Wei Xiang and colleagues in 2026.
It was developed as a replacement for retigabine, which was withdrawn from the market due to toxicity. Fluoxakalner avoids oxidative metabolites like retigabine's thought to be responsible for said toxicity.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1364377384 under CC BY-SA 4.0; modifications have been made.